We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Normal Skin Resists and Rejects Cancerous Growth

By LabMedica International staff writers
Posted on 14 Aug 2017
While examining the biological effects that emerge from interactions between cancerous cells and neighboring normal skin cells, cancer researchers demonstrated the ability of the skin to eliminate the mutant cells.

Investigators at Yale University (New Haven, CT, USA) were particularly keen to understand how tissue in the near vicinity of a tumor remains phenotypically normal, despite the presence of these mutant cells.

To unravel this puzzle, the investigators used advanced imaging techniques to track the fate of mouse skin epithelium burdened with varying numbers of activated Wnt/beta-catenin stem cells. More...
They reported in the August 2, 2017, online edition of the journal Nature that all resulting growths that deformed the skin tissue architecture regressed, irrespective of their size. Wild-type cells were required for the active elimination of mutant cells from the tissue, while utilizing both endogenous and ectopic cellular behaviors to dismantle the aberrant structures.

After regression, the remaining structures were either completely eliminated or converted into functional skin appendages in a niche-dependent manner. Furthermore, tissue aberrancies generated from oncogenic cells, and even mutation-independent deformations to the tissue could also be corrected, indicating that this tolerance phenomenon reflected a conserved principle in the skin.

"The normal cells can even corral and escort mutant cells out of the tissue and clean up the mess the mutant cells left behind, in order to keep the tissue healthy and functional," said first author Samara Brown, a graduate researcher at Yale University.

Related Links:
Yale University


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.